Pacira Pharma (PCRX) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update
May 4, 2021 8:00 AM EDT-- EXPAREL average daily sales at 115% of the prior year first quarter---- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2021.
First Quarter 2021 Financial Highlights
Total revenues of $119.0 millionGAAP... More